- Follow up from a Phase 2 study assessing ARIAD Pharmaceuticals' (ARIA -1.8%) Iclusig (ponatinib) in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) shows that Iclusig continues to demonstrate anti-leukemic activity for an extended period, specifically a median of 3.5 years for chronic phase CML and a median of 2.9 years for all patients in the trial.
- An estimated 83% of chronic phase CML patients who achieved a major cytogenic response (MCyR) have maintained their status at three years as well as 95% of those who underwent ponatinib dose reductions.
- The data were presented at the 20th Congress of the European Hematology Association in Vienna, Austria.